PRIMA BIOMED COMMENCES “CANVAS” CLINICAL TRIAL IN EUROPE
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
(“Prima,” the “Company”) is pleased to announce that it has commenced recruitment of patients into the CANVAS (CANcer VAccine Study) trial in Europe. Prima has authorized several centers in Ukraine to start enrolling patients. CANVAS is a phase 2/3 study of CVacTM for the maintenance treatment of newly diagnosed, late-stage epithelial ovarian cancer patients who achieve remission after optimal debulking surgery and standard first line chemotherapy.
Prima has obtained the requisite ethics and regulatory approvals in multiple European countries, including Belarus, Belgium, Bulgaria, Germany, Lithuania, Latvia, Poland and Ukraine. The Company anticipates that the majority of CANVAS patients will be enrolled in Europe. The trial is currently open for recruitment at a number of centers in the United States and Australia.
Prima BioMed CEO Matthew Lehman said: “We are pleased to open enrollment for the CANVAS trial in Europe; we plan to progressively open sites across several European countries in the coming months. I would like to congratulate our clinical team and our manufacturing colleagues at the Fraunhofer Institute of Cell Therapy and Immunology for bringing us to this milestone.”
Prima maintains updated information about the CANVAS trial and enrolling clinical centers on the U.S. National Institutes of Health clinical trial registry at www.clinicaltrials.gov.
ENDS
About CANVAS
- Forums
- ASX - By Stock
- ann
PRIMA BIOMED COMMENCES “CANVAS” CLINICAL TRIAL IN EUROPEPrima...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
GML
Gateway Mining sells WA Eastern Montague gold project to Brightstar for $14M – half of that in shares
MND
Albemarle lithium downsize burns $200M hole in Monadelphous's pocket as latter's contracts terminated
Add IMM (ASX) to my watchlist
|
|||||
Last
34.0¢ |
Change
0.005(1.49%) |
Mkt cap ! $493.8M |
Open | High | Low | Value | Volume |
33.5¢ | 34.0¢ | 33.0¢ | $1.233M | 3.670M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 484808 | 33.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
34.0¢ | 52319 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
13 | 484808 | 0.330 |
8 | 258954 | 0.325 |
13 | 518704 | 0.320 |
3 | 155001 | 0.315 |
4 | 23010 | 0.310 |
Price($) | Vol. | No. |
---|---|---|
0.340 | 52319 | 5 |
0.345 | 49903 | 2 |
0.350 | 22702 | 4 |
0.355 | 125992 | 5 |
0.360 | 149360 | 5 |
Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
Featured News
AVH
Avita boosts skin restoration product portfolio with 'dermal matrix' – a kind of next-level gauze made of fake skin
TG1
TechGen Metals kicks off airborne geophys survey at Sally Downs copper play – a first for the permit
IMM (ASX) Chart |